XGN
Exagen·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 1
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
Revenue Beats Expectation
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About XGN
Exagen Inc.
A leading provider of autoimmune testing solutions
Healthcare Providers and Services
Invalid Date
09/19/2019
NASDAQ Stock Exchange
203
12-31
Common stock
1261 Liberty Way, Suite C, Vista, California 92081
--
Exagen Inc., was founded in 2002. Exagen is committed to transforming the continuum of care for patients with debilitating and chronic autoimmune diseases through timely differential diagnosis and optimized therapeutic interventions. The company's goal is to enable rheumatologists to improve patient care through differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune related diseases, including SLE and rheumatoid arthritis or RA.
Earnings Call
Q2/2025
Estimate EPS-0.15
Actual EPS-0.21
Estimate Revenue16.31M
Actual Revenue17.20M
Exagen's Q2 2025: Unpacking Contradictions in Volume Growth, ASP Expectations, and Biopharma Revenue
Jul 29,2025 03:17
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
XGN has released its 2025 Q3 earnings. EPS was reported at -0.31, versus the expected -0.16, missing expectations. The chart below visualizes how XGN has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
XGN has released its 2025 Q3 earnings report, with revenue of 17.24M, reflecting a YoY change of 37.87%, and net profit of -7.09M, showing a YoY change of -40.95%. The Sankey diagram below clearly presents XGN's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
